Among the 14 patients receiving treatment, 7 (50%) had stable or relieved disease, indicating that autologous HER2 CAR-T cell therapy for advanced sarcoma patients is safe and has certain anti-tumor activity after lymphocyte clearance (108). Here, ERBB2 is linked to sarcoma.